Pharmacogenomics of antipsychotics efficacy for schizophrenia

Psychiatry and Clinical Neurosciences

Volumn 65, Issue 1, 2011, Pages 3-19

  Cacabelos, Ramõn ^a   Hashimoto, Ryota ^b   Takeda, Masatoshi ^b  

^a Centro de Investigacion Biomedica EuroEspes   (Spain)

^b OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

antipsychotics; CYP 450; pharmacodynamics; pharmacokinetics; schizophrenia

Indexed keywords

ARIPIPRAZOLE; CATECHOL METHYLTRANSFERASE; CHLORPROMAZINE; CLOZAPINE; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; DOPAMINE 4 RECEPTOR; DOPAMINE TRANSPORTER; DYSBINDIN; EMONAPRIDE; HALOPERIDOL; NEU DIFFERENTIATION FACTOR; NEUROLEPTIC AGENT; OLANZAPINE; REELIN; RGS4 PROTEIN; RISPERIDONE; SEROTONIN 1A RECEPTOR; SEROTONIN 2A RECEPTOR; SEROTONIN 2C RECEPTOR; SEROTONIN 6 RECEPTOR; SEROTONIN 7 RECEPTOR; SEROTONIN TRANSPORTER; SEROTONIN UPTAKE INHIBITOR; SYNAPTOSOMAL ASSOCIATED PROTEIN 25; UNINDEXED DRUG;

ARTICLE; COST EFFECTIVENESS ANALYSIS; DEPRESSION; DEPRESSIVE PSYCHOSIS; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG METABOLISM; DRUG RESPONSE; DRUG SAFETY; ENZYME SUBSTRATE; EPIGENETICS; EXTRAPYRAMIDAL SYMPTOM; FUNCTIONAL GENOMICS; GENE EXPRESSION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HUMAN; METABOLOMICS; MOTOR DYSFUNCTION; NEUROTRANSMISSION; OBESITY; PARKINSONISM; PATIENT COMPLIANCE; PHARMACOGENOMICS; PHENOTYPE; POSITIVE SYNDROME; PROTEOMICS; PSYCHOSIS; QT PROLONGATION; RACE DIFFERENCE; SCHIZOPHRENIA; SIGNAL TRANSDUCTION; STRUCTURAL GENOMICS; TARDIVE DYSKINESIA;

ANTIPSYCHOTIC AGENTS; CYTOCHROME P-450 ENZYME SYSTEM; GENES; GENOME-WIDE ASSOCIATION STUDY; HUMANS; PHARMACOGENETICS; RECEPTORS, DOPAMINE; RECEPTORS, SEROTONIN; SCHIZOPHRENIA;

EID: 79251568944     PISSN: 13231316     EISSN: 14401819     Source Type: Journal    
DOI: 10.1111/j.1440-1819.2010.02168.x     Document Type: Article

References (113)

1. Cacabelos R,. Pharmacogenomic biomarkers in neuropsychiatry: the path to personalized medicine in mental disorders. In:, Ritsner MS, (ed.). The Handbook of Neuropsychiatric Biomarkers, Endophenotypes and Genes. Springer, New York, 2009; 3-63.
2. Cacabelos R,. Pharmacogenomics in Alzheimer's disease. Methods Mol. Biol. 2008; 448: 213-357.
3. Cacabelos R, Takeda M,. Pharmacogenomics, nutrigenomics and future therapeutics in Alzheimer's disease. Drugs Future 2006; 31 (Suppl. B): 5-146.
4. Roses AD,. Pharmacogenetics and drug development: the path to safer and more effective drugs. Nat. Rev. Genet. 2004; 5: 645-656.
5. Okugawa G, Kato M, Wakeno M, et al. Randomized clinical comparison of perospirone and risperidone in patients with schizophrenia: Kansai Psychiatric Multicenter Study. Psychiatry Clin. Neurosci. 2009; 63: 322-328.
6. Kwon JS, Jang JH, Kang DH, Yoo SY, Kim YK, Cho SJ,. Long-term efficacy and safety of aripiprazole in patients with schizophrenia, schizophreniform disorder, or schizoaffective disorder: 26-week prospective study. Psychiatry Clin. Neurosci. 2009; 63: 73-81.
7. Tuppurainen H, Kuikka JT, Viinamäki H, Husso M, Tiihonen J,. Dopamine D2/3 receptor binding potential and occupancy in midbrain and temporal cortex by haloperidol, olanzapine and clozapine. Psychiatry Clin. Neurosci. 2009; 63: 529-537.
8. Pariwatcharakul P, Ketumarn P,. Antipsychotic-induced paroxysmal perceptual alteration in a patient with major depressive disorder. Psychiatry Clin. Neurosci. 2009; 63: 429-430.
9. Park SW, Lee JG, Kong BG, et al. Genetic association of BDNF val66met and GSK-3β-50T/C polymorphisms with tardive dyskinesia. Psychiatry Clin. Neurosci. 2009; 63: 433-439.
10. Maly R, Masopust J, Hosak L, Urban A,. Four cases of venous thromboembolism associated with olanzapine. Psychiatry Clin. Neurosci. 2009; 63: 116-118.
11. Srivastava A, Borkar HA, Chandak S,. Olanzapine-induced neuroleptic malignant syndrome in a patient with paranoid schizophrenia. Psychiatry Clin. Neurosci. 2009; 63: 119-121.
12. Ozbulut O, Emul M, Guler O, Gecici O,. Tardive dyskinesia with ziprasidone and citalopram use in an elderly female patient. Psychogeriatrics 2008; 8: 96-97.
13. Ushijima M, Yokoyama S, Sugiyama E, Amano N,. Contribution of perospirone and risperidone to reduce delirium in senile patients. Psychogeriatrics 2008; 8: 4-7.
14. Ikezawa K, Canuet L, Ishii R, et al. Efficacy of risperidone in the treatment of delirium in elderly patients. Psychogeriatrics 2008; 8: 62-65.
15. Peritogiannis V, Stefanou E, Lixouriotis C, Gkogkos C, Rizos DV,. Atypical antipsychotics in the treatment of delirium. Psychiatry Clin. Neurosci. 2009; 63: 623-631.
16. Hamuro A, Isono H, Sugai Y, Mimura M, Kamijima K,. Characteristics of behavioral and psychological symptoms of dementia in untreated oldest old Alzheimer's disease. Psychogeriatrics 2008; 8: 8-11.
17. Umene W, Yoshimura R, Hori H, Nakamura J,. A case of vascular depression associated with musical hallucinations successfully treated with paroxetine and a low dose of risperidone. Psychogeriatrics 2008; 8: 38-41.
18. Kendurkar A,. Catatonia in an Alzheimer's dementia patient. Psychogeriatrics 2008; 8: 42-44.
19. Kosaka K,. Behavioral and psychological symptoms of dementia (BPSD) in dementia with Lewy bodies. Psychogeriatrics 2008; 8: 134-136.
20. Mizukami K,. Kampo therapy as an alternative to pharmacotherapy using antipsychotic medicines for BPSD. Psychogeriatrics 2008; 8: 137-141.
21. Kimura T, Hayashida H, Furukawa H, Miyauchi D, Takamatsu J,. Five cases of frontotemporal dementia with behavioral symptoms improved by Yokukansan. Psychogeriatrics 2009; 9: 38-43.
22. Amano N, Inuzuka S, Ogihara T,. Behavioral and psychological symptoms of dementia and medical treatment. Psychogeriatrics 2009; 9: 45-49.
23. Kutsumi M, Ito M, Sugiura K, Terabe M, Mikami H,. Management of behavioral and psychological symptoms of dementia in long-term care facilities in Japan. Psychogeriatrics 2009; 9: 186-195.
24. Konishi K, Hori K, Oda T, et al. Effects of aging on behavioral symptoms in Alzheimer's disease. Psychogeriatrics 2009; 9: 11-16.
25. Takita M,. How to treat BPSD; do not treat patients exhibiting symptoms like BPSD with neuroleptics from the beginning. Psychogeriatrics 2008; 8: 148-150.
26. Ihara H, Arai H,. Ethical dilemma associated with the off-label use of antipsychotic drugs for the treatment of behavioral and psychological symptoms of dementia. Psychogeriatrics 2008; 8: 32-37.
27. Malhotra AK, Lencz T, Correll CU, Kane JM,. Genomics and the future of pharmacotherapy in psychiatry. Int. Rev. Psychiatry 2007; 19: 523-530.
28. Nnadi CU, Malhorta AK,. Individualizing antipsychotic drug therapy in schizophrenia: the promise of pharmacogenetics. Curr. Psychiatry Rep. 2007; 9: 313-318.
29. Foster A, Miller D, Buckley PF,. Pharmacogenetics and schizophrenia. Psychiatr. Clin. North. Am. 2007; 30: 417-435.
30. Arranz MJ, de Leon J,. Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research. Mol. Psychiatry 2007; 12: 707-747.
31. Mizutani T,. PM frequencies of major CYPs in Asians and Caucasians. Drug Metab. Rev. 2003; 35: 99-106.
32. Xie HG, Prasad HG, Kim RB, et al. CYP2C9 allelic variants: ethnic distribution and functional significance. Adv. Drug Deliv. Rev. 2002; 54: 1257-1270.
33. Isaza CA, Henao J, Lõpez AM, Cacabelos R,. Isolation, sequence and genotyping of the drug metabolizer CYP2D6 gene in the Colombian population. Methods Find. Exp. Clin. Pharmacol. 2000; 22: 695-705.
34. Ozawa S, Soyama A, Saeki M, et al. Ethnic differences in genetic polymorphisms of CYP2D6, CYP2C19, CYP3As and MDR1/ABCB1. Drug Metab. Pharmacokinet. 2004; 19: 83-95.
35. Xie HG, Kim RB, Wood AJ, et al. Molecular basis of ethnic differences in drug disposition and response. Annu. Rev. Pharm. Toxicol. 2001; 41: 815-850.
36. Madan A, Graham RA, Carroll KM, et al. Effects of prototypical microsomal enzyme inducers on cytochrome P450 expression in cultured human hepatocytes. Drug Metab. Dispos. 2003; 31: 421-431.
37. Hedlund E, Gustafsson JA, Warner M,. Cytochrome P450 in the brain: a review. Curr. Drug Metabol. 2001; 2: 245-263.
38. Funae Y, Kishimoto W, Cho T, et al. CYP2D in the brain. Drug Metab. Pharmacokinet. 2003; 18: 337-349.
39. Scordo MG, Spina E,. Cytochrome P450 polymorphisms and response to antipsychotic therapy. Pharmacogenomics 2002; 3: 201-218.
40. Ingelman-Sundberg M, Sim SC, Gõmez A, et al. Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol. Ther. 2007; 116: 496-526.
41. Kobylecki CJ, Jakobsen KD, Hansen T, et al. CYP2D6 genotype predicts antipsychotic side effects in schizophrenia inpatients: a retrospective matched case-control study. Neuropsychobiology 2009; 59: 222-226.
42. Kang RH, Jung SM, Kim KA, et al. Effects of CYP2D6 and CYP3A5 genotypes on the plasma concentrations of risperidone and 9-hydroxyrisperidone in Korean schizophrenic patients. J. Clin. Psychopharmacol. 2009; 29: 272-277.
43. Yagihashi T, Mizuno M, Chino B, et al. Effects of the CYP2D6*10 alleles fand co-medication with CYP2D6-dependent drugs on risperidone metabolism in patients with schizophrenia. Hum. Psychopharmacol. 2009; 24: 301-308.
44. Fleeman N, McLeod C, Bagust A, et al. The clinical effectiveness and cost-effectiveness of testing for cytochrome P450 polymorphisms in patients with schizophrenia treated with antipsychotics: a systematic review and economic evaluation. Health Technol. Assess. 2010; 14: 1-182.
45. Müller DJ, Zai CC, Sicard M, et al. Systematic analysis of dopamine receptor genes (DRD1-DRD5) in antipsychotic-induced weight gain. Pharmacogenomics J. 2010. doi:10.1038/tpj.2010.65
46. Buchanan RW, Freedman R, Javitt DC, et al. Recent advances in the development of novel pharmacological agents for the treatment of cognitive impairments in schizophrenia. Schizophr. Bull. 2007; 33: 1120-1130.
47. Suzuki A, Kondo T, Mihara K, et al. Association between TaqI A dopamine D2 receptor polymorphism and therapeutic response to bromperidol: a preliminary report. Eur. Arch. Psychiatry Clin. Neurosci. 2001; 251: 57-59.
48. Wu S, Xing Q, Gao R, et al. Response to chlorpromazine treatment may be associated with polymorphisms of the DRD2 gene in Chinese schizophrenic patients. Neurosci. Lett. 2005; 376: 1-4.
49. Arranz MJ, Li T, Munro J, et al. Lack of association between a polymorphism in the promoter region of the dopamine-2 receptor gene and clozapine response. Pharmacogenetics 1998; 8: 481-484. (Pubitemid 29043380)
50. Hwang R, Shinkai T, De Luca V, et al. Association study of 12 polymorphisms spanning the dopamine D(2) receptor gene and clozapine treatment response in two treatment refractory/intolerant populations. Psychopharmacology 2005; 181: 179-187.
51. Reynolds GP, Yao Z, Zhang X, Sun J, Zhang Z,. Pharmacogenetics of treatment in first-episode schizophrenia: D3 and 5-HT2C receptor polymorphisms separately associate with positive and negative symptom response. Eur. Neuropsychopharmacol. 2005; 15: 143-151.
52. Rao PA, Pickar D, Gejman PV, Ram A, Gershon ES, Gelernter J,. Allelic variation in the D4 dopamine receptor (DRD4) gene does not predict response to clozapine. Arch. Gen. Psychiatry 1994; 51: 912-917.
53. Shaikh S, Collier D, Kerwin RW, et al. Dopamine D4 receptor subtypes and response to clozapine. Lancet 1993; 341: 116.
54. Shaikh S, Collier DA, Sham P, et al. Analysis of clozapine response and polymorphisms of the dopamine D4 receptor gene (DRD4) in schizophrenic patients. Am. J. Med. Genet. 1995; 60: 541-545.
55. Rietschel M, Naber D, Oberlander H, et al. Efficacy and side-effects of clozapine: testing for association with allelic variation in the dopamine D4 receptor gene. Neuropsychopharmacology 1996; 15: 491-496.
56. Kohn Y, Ebstein RP, Heresco-Levy U, et al. Dopamine D4 receptor gene polymorphisms: relation to ethnicity, no association with schizophrenia and response to clozapine in Israeli subjects. Eur. Neuropsychopharmacol. 1997; 7: 39-43.
57. Cohen BM, Ennulat DJ, Centorrino F, et al. Polymorphisms of the dopamine D4 receptor and response to antipsychotic drugs. Psychopharmacology (Berl) 1999; 141: 6-10.
58. Zhao AL, Zhao JP, Zhang YH, et al. Dopamine D4 receptor gene exon III polymorphism and interindividual variation in response to clozapine. Int. J. Neurosci. 2005; 115: 1539-1547.
59. Hwu HG, Hong CJ, Lee YL, Lee PC, Lee SF,. Dopamine D4 receptor gene polymorphisms and neuroleptic response in schizophrenia. Biol. Psychiatry 1998; 44: 483-487.
60. Szekeres G, Keri S, Juhasz A, et al. Role of dopamine D3 receptor (DRD3) and dopamine transporter (DAT) polymorphism in cognitive dysfunctions and therapeutic response to atypical antipsychotics in patients with schizophrenia. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2004; 124: 1-5.
61. Lane HY, Hsu SK, Liu YC, Chang YC, Huang CH, Chang WH,. Dopamine D3 receptor Ser9Gly polymorphism and risperidone response. J. Clin. Psychopharmacol. 2005; 25: 6-11.
62. Chen SF, Shen YC, Chen CH,. Effects of the DRD3 Ser9Gly polymorphism on aripiprazole efficacy in schizophrenic patients as modified by clinical factors. Prog. Neuropsychopharmacol. Biol. Psychiatry 2009; 33: 470-474.
63. Joober R, Toulouse A, Benkelfat C, et al. DRD3 and DAT1 genes in schizophrenia: an association study. J. Psychiatry Res. 2000; 34: 285-291.
64. Zhang A, Xing Q, Wang L, et al. Dopamine transporter polymorphisms and risperidone response in Chinese schizophrenia patients: an association study. Pharmacogenomics 2007; 8: 1337-1345. (Pubitemid 350162849)
65. Arranz MJ, Munro J, Sham P, et al. Meta-analysis of studies on genetic variation in 5-HT2A receptors and clozapine response. Schizophr. Res. 1998; 32: 93-99.
66. Lane HY, Chang YC, Chiu CC, Chen ML, Hsieh MH, Chang WH,. Association of risperidone treatment response with a polymorphism in the 5-HT(2A) receptor gene. Am. J. Psychiatry 2002; 159: 1593-1595.
67. Iwahashi K, Murayama O, Aoki J, et al. Influence of serotonin (5-HT) 2A-receptor and transporter (5HTT) gene polymorphism upon the effect of olanzapine. Nihon Shinkei Seishin Yakurigaku Zasshi 2009; 29: 141-144.
68. Herken H, Erdal ME, Esgi K, Virit O, Aynacioglu AS,. The relationship between the response to risperidone treatment and HT2A receptor gene (T102C and 1438G/A) polymorphism in schizophrenia. Bull. Clin. Psychopharmacol. 2003; 13: 161-166.
69. Chen SF, Shen YC, Chen CH,. HTR2A A-1438G/T102C polymorphisms predict negative symptoms performance upon aripiprazole treatment in schizophrenic patients. Psychopharmacology (Berl) 2009; 205: 285-292.
70. Reynolds GP, Arranz B, Templeman LA, et al. Effect of 5-HT1A receptor gene polymorphism on negative and depressive symptom response to antipsychotic treatment of drug-naive psychotic patients. Am. J. Psychiatry 2006; 163: 1826-1829.
71. Sodhi MS, Arranz MJ, Curtis D, et al. Association between clozapine response and allelic variation in the 5-HT2C receptor gene. Neuroreport 1995; 7: 169-172.
72. Veenstra-VanderWeele J, Anderson GM, Cook EH Jr,. Pharmacogenetics and the serotonin system: initial studies and future directions. Eur. J. Pharmacol. 2000; 410: 165-181.
73. Yu YW, Tsai SJ, Lin CH, Hsu CP, Yang KH, Hong CJ,. Serotonin-6 receptor variant (C267T) and clinical response to clozapine. Neuroreport 1999; 10: 1231-1233.
74. Lane HY, Lee CC, Chang YC, Lu CT, Huang CH, Chang WH,. Effects of dopamine D2 receptor Ser311Cys polymorphism and clinical factors on risperidone efficacy for positive and negative symptoms and social function. Int. J. Neuropsychopharmacol. 2004; 7: 461-470.
75. Wei Z, Wang L, Xuan J, et al. Association analysis of serotonin receptor 7 gene (HTR7) and risperidone response in Chinese schizophrenia patients. Prog. Neuropsychopharmacol. Biol. Psychiatry 2009; 33: 547-551.
76. Arranz MJ, Munro J, Birkett J, et al. Pharmacogenetic prediction of clozapine response. Lancet 2000; 355: 1615-1616.
77. Kaiser R, Tremblay PB, Schmider J, et al. Serotonin transporter polymorphisms: no association with response to antipsychotic treatment, but associations with the schizoparanoid and residual subtypes of schizophrenia. Mol. Psychiatry 2001; 6: 179-185.
78. Harrison PJ, Weinberger DR,. Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence. Mol. Psychiatry 2005; 10: 40-68.
79. Zuo L, Luo X, Krystal JH, et al. The efficacies of clozapine and haloperidol in refractory schizophrenia are related to DTNBP1 variation. Pharmacogenet. Genomics 2009; 19: 437-446.
80. Kampman O, Anttila S, Illi A, et al. Neuregulin genotype and medication response in Finnish patients with schizophrenia. Neuroreport 2004; 15: 2517-2520.
81. Mouaffak F, Kebir O, Chayet M, et al. Association of Disrupted in Schizophrenia 1 (DISC1) missense variants with ultra-resistant schizophrenia. Pharmacogenomics J. 2010. doi:10.1038/tpj.2010.40
82. Illi A, Mattila KM, Kampman O, et al. Catechol-O-methyltransferase and monoamine oxidase A genotypes and drug response to conventional neuroleptics in schizophrenia. J. Clin. Psychopharmacol. 2003; 23: 429-434.
83. Illi A, Kampman O, Hänninen K, et al. Catechol-O-methyltransferase val108/158met genotype and response to antipsychotic medication in schizophrenia. Hum. Psychopharmacol. 2007; 22: 211-215.
84. Gupta M, Bhatnagar P, Grover S, et al. Association studies of catechol-O-methyltransferase (COMT) gene with schizophrenia and response to antipsychotic treatment. Pharmacogenomics 2009; 10: 385-397.
85. Levitt P, Evert P, Mirnics K, Nimgaonkar VL, Lewis DA,. Making the case for a candidate vulnerability gene in schizophrenia; convergent evidence for regulator of G-protein signaling-4 (RGS4). Biol. Psychiatry 2006; 60: 534-537.
86. Mirnics K, Middleton FA, Stanwood GD, Lewis DA, Levitt P,. Disease-specific changes in regulator of G-protein signaling 4 (RGS4) expression in schizophrenia. Mol. Psychiatry 2001; 6: 293-301.
87. Campbell DB, Ebert PJ, Skelly T, et al. Ethnic stratification of the association of RGS4 variants with antipsychotic treatment response in schizophrenia. Biol. Psychiatry 2008; 63: 32-41.
88. Lane HY, Liu YC, Huang CL, et al. RGS4 polymorphisms predict clinical manifestations and responses to risperidone treatment in patients with schizophrenia. J. Clin. Psychopharmacol. 2008; 28: 64-68.
89. Hong CJ, Yu YW, Lin CH, Tsai SJ,. An association study of a brain-derived neurotrophic factor Val66Met polymorphism and clozapine response of schizophrenic patients. Neurosci. Lett. 2003; 349: 206-208.
90. Anttila S, Illi A, Kampman O, Mattila KM, Lehtimaki T, Leinonen E,. Lack of association between two polymorphisms of brain-derived neurotrophic factor and response to typical neuroleptics. J. Neural. Transm. 2005; 112: 885-890.
91. Krebs MO, Guillin O, Bourdell MC, et al. Brain derived neurotrophic factor (BDNF) gene variants association with age at onset and therapeutic response in schizophrenia. Mol. Psychiatry 2000; 5: 558-562.
92. Park SW, Lee JG, Ha EK, et al. Differential effects of aripiprazole and haloperidol on BDNF-mediated signal changes in SH-SY5Y cells. Eur. Neuropsychopharmacol. 2009; 19: 356-362.
93. Fatemi SH, Reutiman TJ, Folsom TD,. Chronic psychotropic drug treatment causes differential expression of Reelin signaling system in frontal cortex of rats. Schizophr. Res. 2009; 111: 138-152.
94. Guidotti A, Dong E, Kundakovic M, et al. Characterization of the action of antipsychotic subtypes on valproate-induced chromatin remodeling. Trends Pharmacol. Sci. 2009; 30: 55-60.
95. Chana G, Lucero G, Salaria S, et al. Upregulation of NRG-1 and VAMP-1 in human brain aggregates exposed to clozapine. Schizophr. Res. 2009; 113: 273-276.
96. Müller DJ, Klempan TA, De Luca V, et al. The SNAP-25 gene may be associated with clinical response and weight gain in antipsychotic treatment of schizophrenia. Neurosci. Lett. 2005; 379: 81-89.
97. Ji B, La Y, Gao L, et al. A comparative proteomics analysis of rat mitochondria from the cerebral cortex and hippocampus in response to antipsychotic medications. J. Proteome Res. 2009; 8: 3633-3641.
98. Choi KH, Higgs BW, Weis S, et al. Effects of typical and atypical antipsychotic drugs on gene expression profiles in the liver of schizophrenia subjects. BMC Psychiatry 2009; 9: 57.
99. Ma D, Chan MK, Lockstone HE, et al. Antipsychotic treatment alters protein expression associated with presynaptic function and nervous system development in rat frontal cortex. J. Proteome Res. 2009; 8: 3284-3297.
100. Aberg K, Adkins DE, Bukszár J, et al. Genomewide association study of movement-related adverse antipsychotic effects. Biol. Psychiatry 2010; 67: 279-282.
101. Alkelai A, Greenbaum L, Rigbi A, Kanyas K, Lerer B,. Genome-wide association study of antipsychotic-induced parkinsonism severity among schizophrenia patients. Psychopharmacology (Berl) 2009; 206: 491-499.
102. Volpi S, Heaton C, Mack K, et al. Whole genome association study identifies polymorphisms associated with QT prolongation during iloperidone treatment of schizophrenia. Mol. Psychiatry 2009; 14: 1024-1031.
103. Chagnon YC, Mérette C, Bouchard RH, Emond C, Roy MA, Maziade M,. A genome wide linkage study of obesity as secondary effect of antipsychotics in multigenerational families of eastern Quebec affected by psychoses. Mol. Psychiatry 2004; 9: 1067-1074.
104. McClay JL, Adkins DE, Aberg K, et al. Genome-wide pharmacogenomic analysis of response to treatment with antipsychotics. Mol. Psychiatry 2009. doi:10.1038/mp.2009.89
105. Lavedan C, Licamele L, Volpi S, et al. Association of the NPAS3 gene and five other loci with response to the antipsychotic iloperidone identified in a whole genome association study. Mol. Psychiatry 2009; 14: 804-819.
106. Ikeda M, Tomita Y, Mouri A, et al. Identification of novel candidate genes for treatment response to risperidone and susceptibility for schizophrenia: integrated analysis among pharmacogenomics, mouse expression, and genetic case-control association approaches. Biol. Psychiatry 2010; 67: 263-269.
107. Volpi S, Potkin SG, Malhotra AK, et al. Applicability of a genetic signature for enhanced iloperidone efficacy in the treatment of schizophrenia. J. Clin. Psychiatry 2009; 70: 801-809.
108. dell'aversano C, Tomasetti C, Iasevoli F, et al. Antipsychotic and antidepressant co-treatment: effects on transcripts of inducible postsynaptic density genes possibly implicated in behavioural disorders. Brain Res. Bull. 2009; 79: 123-129.
109. Philips KA, Van Bebber SL,. Measuring the value of pharmacogenomics. Nat. Rev. Drug Discovery 2005; 4: 500-509.
110. Veenstra DL, Higashi MK,. Assessing the cost-effectiveness of pharmacogenomics. AAPS Pharm. Sci. 2000; 2: 80-90.
111. Roses AD,. The medical and economic roles of pipeline pharmacogenetics: Alzheimer's disease as a model of efficacy and HLA-B(*)5701 as a model of safety. Neuropsychopharmacology 2009; 34: 6-17.
112. Pascussi JM, Gerbal-Chaloin S, Drocourt L, et al. The expression of CYP2B6, CYP2C9 and CYP2A4 genes: a tangle of networks of nuclear and steroid receptors. Biochim. Biophys. Acta 2003; 1619: 243-253.
113. Honkakoski P, Negishi M,. Regulation of cytochrome P450 (CYP) genes by nuclear receptors. Biochem. J. 2000; 347: 321-337.